Comparison of the effect of two doses of filgrastim in the treatment of neutropenia
Phase 2
Completed
- Conditions
- eutropenia.Neutropenia
- Registration Number
- IRCT20180103038196N8
- Lead Sponsor
- Gorgan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
patients with cancer associated with neutropenia
Parents' informed consent for their child's participation in the study
patients with absolute neutrophil count<1500 with one of the following items:
Neutropenia lasts for more than 7-10 days
Low blood pressure
Profound neutropenia
Sepsis
pneumonia
fungal infections
Exclusion Criteria
Patients with less than 1500 neutrophils while they have active leukemia or their leukemia is not in the remission phase.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ANC increase rate. Timepoint: Each 48 hours will be done, and when the ANC is over 1500, the medication will be discontinued. Method of measurement: Study of CBC Elements.;Number of hospitalization days. Timepoint: Hospitalize duration. Method of measurement: from patient documents.;Number of days that patient received antibiotics. Timepoint: Hospitalize duration. Method of measurement: from patient documents.;Time taken to stop the fever. Timepoint: Hospitalize duration. Method of measurement: from patient documents.
- Secondary Outcome Measures
Name Time Method